Australians with chronic lymphocytic leukaemia continue to have high rates of second primary malignancies in the modern era
Internal Medicine Journal · 2024
DOI: 10.1111/imj.16445 ↗Kurz gefasst
Fachartikel in der Zeitschrift Internal Medicine Journal, 2024. Verfasst von Diva Baggio und 19 weiteren Autor:innen. Beteiligte Einrichtung: Olivia Newton-John Cancer Research and Wellness Centre, Austin Health, Melbourne, Victoria, Australia. Hauptthemen laut MEDLINE: Leukemia, Lymphocytic, Chronic, B-Cell, Neoplasms, Second Primary. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Janssen Pharmaceutica.
Abstract (Originalsprache)
Population‐based studies have demonstrated a high risk of second cancers, especially of the skin, among patients with chronic lymphocytic leukaemia (CLL). We describe age‐standardised incidence ratios (SIRs) of second primary malignancies (SPM) in Australian patients with relapsed/refractory CLL treated with at least two lines of therapy, including ibrutinib. From December 2014 to November 2017, 156 patients were identified from 13 sites enrolled in the Australasian Lymphoma and Related Diseases Registry, and 111 had follow‐up data on rates of SPM. At 38.4 months from ibrutinib therapy commencement, 25% experienced any SPM. SIR for melanoma and all cancers (excluding nonmelanomatous skin cancers) were 15.8 (95% confidence interval (CI): 7.0–35.3) and 4.6 (95% CI: 3.1–6.9) respectively. These data highlight the importance of primary preventive interventions and surveillance, particularly as survival from CLL continues to improve.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Olivia Newton-John Cancer Research and Wellness Centre, Austin Health, Melbourne, Victoria, Australia.
- Monash University, Melbourne, Victoria, Australia.
- Ballarat Regional Integrated Cancer Centre, Ballarat, Victoria, Australia.
- Gold Coast University Hospital, Gold Coast, Queensland, Australia.
- Sir Charles Gairdner Hospital, Perth, Western Australia, Australia.
- Royal Adelaide Hospital, Adelaide, South Australia, Australia.
ORCID-Profile: Diva Baggio, Tara Cochrane, Nada Hamad, Dipti Talaulikar, Erica Wood, Eliza Hawkes
Förderung
- Janssen Pharmaceutica
Zitieren
APA
Baggio, D., Chung, E., Wellard, C., Waters, N., Cushion, T., Chong, G., Cochrane, T., Cull, G., Giri, P., Hamad, N., Johnston, A., Lee, D., Murali, A., Morgan, S., Mulligan, S., Talaulikar, D., Ratnasingam, S., Wood, E., Hawkes, E., & Opat, S. (2024). Australians with chronic lymphocytic leukaemia continue to have high rates of second primary malignancies in the modern era. Internal Medicine Journal. https://doi.org/10.1111/imj.16445
Vancouver
Baggio D, Chung E, Wellard C, Waters N, Cushion T, Chong G, et al. Australians with chronic lymphocytic leukaemia continue to have high rates of second primary malignancies in the modern era. Internal Medicine Journal. 2024. doi:10.1111/imj.16445
BibTeX
@article{Baggio2024,
author = {Baggio, Diva and Chung, Eliza and Wellard, Cameron and Waters, Neil and Cushion, Tania and Chong, Geoffrey and Cochrane, Tara and Cull, Gavin and Giri, Pratyush and Hamad, Nada and Johnston, Anna and Lee, Denise and Murali, Aarya and Morgan, Susan and Mulligan, Stephen and Talaulikar, Dipti and Ratnasingam, Sumita and Wood, Erica and Hawkes, Eliza and Opat, Stephen},
title = {Australians with chronic lymphocytic leukaemia continue to have high rates of second primary malignancies in the modern era},
journal = {Internal Medicine Journal},
year = {2024},
doi = {10.1111/imj.16445}
}
EUVIMED